Female pattern hair loss is mechanistically distinct from male AGA. While androgens (including DHT) play a role, the picture in women involves estrogen decline (particularly perimenopausal/postmenopausal), thyroid sensitivity, and individual variation in how aggressively scalp follicles respond to circulating androgens. The combination strategy targets these multiple drivers in parallel. The foundation pairing is minoxidil + topical spironolactone — analogous to fin+min in men. Oral spironolactone + minoxidil is the established standard-of-care female combination, and a 2025 comparative RCT (Hassan et al., n=80) demonstrated topical spironolactone 1% gel produces clinical and trichoscopic improvement comparable to topical minoxidil 5% gel. Anagen's protocol uses both — at a lower spironolactone concentration (0.25%) than the studied 1%. On top of that foundation, estriol provides the estrogenic axis (the closest published analog is 17α-estradiol 0.025%, which has phase IV trial data showing significant hair count improvement in female pattern loss). T3 and levocetirizine add their respective mechanisms. The lower estriol and spironolactone doses are calibrated to balance combination breadth against systemic exposure — a concern in women, particularly those of reproductive age.